Clinical trials of antibody therapy

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

1997 • 3,152 citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

1999 • 2,656 citations

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

1999 • 2,358 citations

The CD40 Antigen and its Ligand

1994 • 1,259 citations

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1982 • 1,001 citations

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1997 • 886 citations

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1999 • 755 citations

Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

1994 • 632 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1998 • 530 citations

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

2000 • 485 citations

Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety

1999 • 459 citations

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

1995 • 447 citations

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1999 • 440 citations

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1999 • 423 citations

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

1996 • 410 citations

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1989 • 356 citations

Fc receptors are required in passive and active immunity to melanoma

1998 • 322 citations

HOW DO MONOCLONAL ANTIBODIES INDUCE TOLERANCE? A Role for Infectious Tolerance?

1998 • 223 citations

Regulation of the Complement Membrane Attack Pathway

1999 • 221 citations

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1997 • 218 citations

Human antibodies by design

1998 • 157 citations

Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment

1998 • 150 citations

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

1998 • 131 citations

Mice carrying a CD20 gene disruption

1998 • 129 citations

Signaling antibodies in cancer therapy

1999 • 127 citations

Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein

1994 • 121 citations

Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes

1997 • 107 citations

Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors

1998 • 106 citations

Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety

2007 • 102 citations

The Development of Monoclonal Antibodies for the Therapy of Cancer

1998 • 80 citations

Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.

1995 • 69 citations

A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation

1999 • 67 citations

Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy

1999 • 67 citations

Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL1 Tumor After Dormancy Is Established

1997 • 56 citations

Immunotherapy of endotoxemia and septicemia

1993 • 49 citations

Antibodies Stage a Comeback in Cancer Treatment

1998 • 45 citations

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1998 • 44 citations

TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY

1995 • 37 citations

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice

1997 • 31 citations

The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma

1999 • 29 citations

Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology

2000 • 21 citations

Radioimmunotherapy of B-cell lymphoma

1991 • 15 citations